In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue 6, 2006, Pages 509-514

  Tinto, Halidou ^a,d,e   Rwagacondo, Claude ^b   Karema, Corinne ^b   Mupfasoni, Denise ^b   Vandoren, Waltruda ^b   Rusanganwa, Emmanuel ^c   Erhart, Annette ^d   Van Overmeir, Chantal ^d   Van Marck, Eric ^e   D'Alessandro, Umberto ^d  

^a CENTRE MURAZ   (Burkina Faso)

^b National Malaria Control Program   (Rwanda)

^c Laboratoire National de Santé Publique   (Rwanda)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Chloroquine; Dihydroartemisinin; Malaria; Monodesethylamodiaquine; Plasmodium falciparum; Quinine; Rwanda

Indexed keywords

AMODIAQUINE; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; FANSIDAR; QUININE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD SAMPLING; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; FEMALE; HUMAN; IC 50; IN VITRO STUDY; MALARIA FALCIPARUM; MALE; NONHUMAN; PARASITE ISOLATION; PARASITEMIA; RWANDA;

ADOLESCENT; ADULT; AMODIAQUINE; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INFANT; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; QUININE; RWANDA; SESQUITERPENES;

PLASMODIUM FALCIPARUM;

EID: 33646472123     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2005.09.018     Document Type: Article

References (35)

1. Adjuik M., Agnamey P., Babiker A., Borrmann S., Brasseur P., Cisse M., Cobelens F., Diallo S., Faucher J.F., Garner P., Gikunda S., Kremsner P.G., Krishna S., Lell B., Loolpapit M., Matsiegui P.B., Missinou M.A., Mwanza J., Ntoumi F., Olliaro P., Osimbo P., Rezbach P., Some E., and Taylor W.R. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359 (2002) 1365-1372
2. Aubouy A., Mayombo J., Keundjian A., Bakary M., Le Bras J., and Deloron P. Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am. J. Trop. Med. Hyg. 71 (2004) 294-296
3. Basco L.K., Ndounga M., Keundjian A., and Ringwald P. Molecular epidemiology of malaria in Cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children. Am. J. Trop. Med. Hyg. 66 (2002) 117-123
4. Batty K.T., Thu L.T., Davis T.M., Ilett K.F., Mai T.X., Hung N.C., Tien N.P., Powell S.M., Thien H.V., Binh T.Q., and Kim N.V. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45 (1998) 123-129
5. Bloland P.B., and Ruebush T.K. Amodiaquine. Lancet 348 (1996) 1659-1660
6. Brasseur P., Guiguemde R., Diallo S., Guiyedi V., Kombila M., Ringwald P., and Olliaro P. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 645-650
7. Desjardins R.E., Canfields C.J., Haynes J.P., and Chnulay J.D. Quantitative assessment of antimalarial activity in vitro by a semi-automated microdilution technique. Antimicrob. Agents Chemother. 16 (1979) 710-718
8. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52 (2001) 349-355
9. Gonzalez I.J., Varela R.E., Murillo C., Ferro B.E., Salas J., Giraldo L.E., Zalis M.G., and Saravia N.G. Polymorphisms in cg2 and Pfcrt genes and resistance to chloroquine and other antimalarials in vitro in Plasmodium falciparum isolates from Colombia. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 318-324
10. Gorissen E., Ashruf G., Lamboo M., Bennebroek J., Gikunda S., Mbaruku G., and Kager P.A. In vivo efficacy study of amodiaquine and sulfadoxine/pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Trop. Med. Int. Health 5 (2000) 459-463
11. Grace J.M., Aguilar A.J., Trotman K.M., Peggins J.O., and Brewer T.G. Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos. 26 (1998) 313-317
12. Kilimali V.A. The in vitro response of Plasmodium falciparum to amodiaquine, quinine and quinidine in Tanga region, Tanzania. East Afr. Med. J. 67 (1990) 336-340
13. Lee I.S., and Hufford C.D. Metabolism of antimalarial sesquiterpene lactones. Pharmacol. Ther. 48 (1990) 345-355
14. Li X.Q., Bjorkman A., Andersson T.B., Ridderstrom M., and Masimirembwa C.M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300 (2002) 399-407
15. McIntosh H.M., and Olliaro P. Artemisinin derivatives for treating severe malaria. The Cochrane Database of Systematic Reviews: The Cochrane Library. 4th ed. (2003), John Wiley & Sons Ltd, Chichester
16. Mutanda L.N. Assessment of drug resistance to the malaria parasite in residents of Kampala, Uganda. East Afr. Med. J. 76 (1999) 421-424
17. Noedl H., Wernsdorfer W.H., Krudsood S., Wilairatana P., Viriyavejakul P., Kollaritsch H., Wiedermann G., and Looareesuwan S. In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance. Am. J. Trop. Med. Hyg. 65 (2001) 696-699
18. Ouédraogo J.B., Dutheil Y., Tinto H., Traore B., Zampa H., Tall F., Coulibaly S.O., and Guiguemde T.R. In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa). Trop. Med. Int. Health 3 (1998) 381-384
19. Pettinelli F., Pettinelli M.E., Eldin de Pecoulas P., Millet J., Michel D., Brasseur P., and Druilhe P. Short report: high prevalence of multidrug-resistant Plasmodium falciparum malaria in the French territory of Mayotte. Am. J. Trop. Med. Hyg. 70 (2004) 635-637
20. Pradines B., Mabika Mamfoumbi M., Parzy D., Owono Medang M., Lebeau C., Mourou Mbina J.R., Doury J.C., and Kombila M. In vitro susceptibility of Gabonese wild isolates of Plasmodium falciparum to artemether, and comparison with chloroquine, quinine, halofantrine and amodiaquine. Parasitology 117 (1998) 541-545
21. Pradines B., Rogier C., Fusai T., Tall A., Trape J.F., and Doury J.C. In vitro activity of artemether against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. Am. J. Trop. Med. Hyg. 58 (1998) 354-357
22. Pradines B., Tall A., Parzy D., Spiegel A., Fusai T., Hienne R., Trape J.F., and Doury J.C. In vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J. Antimicrob. Chemother. 42 (1998) 333-339
23. Ringwald P., Bickii J., and Basco L.K. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde. Am. J. Trop. Med. Hyg. 61 (1999) 187-192
24. Ringwald P., Meche F.S., Bickii J., and Basco L.K. In vitro culture and drug sensitivity assay of Plasmodium falciparum with nonserum substitute and acute-phase sera. J. Clin. Microbiol. 37 (1999) 700-705
25. Rwagacondo C.E., Niyitegeka F., Sarushi J., Karema C., Mugisha V., Dujardin J.C., Van Overmeir C., van den Ende J., and D'Alessandro U. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine-pyrimethamine combined with artesunate. Am. J. Trop. Med. Hyg. 68 (2003) 743-747
26. Rwagacondo C.E., Karema C., Mugisha V., Erhart A., Dujardin J.C., Van Overmeir C., Ringwald P., and D'Alessandro U. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop. Med. Int. Health 9 (2004) 1091-1098
27. Schellenberg D., Kahigwa E., Drakeley C., Malende A., Wigayi J., Msokame C., Aponte J.J., Tanner M., Mshinda H., Menendez C., and Alonso P.L. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 67 (2002) 17-23
28. Shmuklarsky M.J., Klayman D.L., Milhous W.K., Kyle D.E., Rossan R.N., Ager Jr. A.L., Tang D.B., Heiffer M.H., Canfield C.J., and Schuster B.G. Comparison of beta-artemether and beta-arteether against malaria parasites in vitro and in vivo. Am. J. Trop. Med. Hyg. 48 (1993) 377-384
29. Shretta R., Omumbo J., Rapuoda B., and Snow R.W. Using evidence to change antimalarial drug policy in Kenya. Trop. Med. Int. Health 5 (2000) 755-764
30. Staedke S.G., Kamya M.R., Dorsey G., Gasasira A., Ndeezi G., Charlebois E.D., and Rosenthal P.J. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358 (2001) 368-374
31. Tinto H., Ouédraogo J.B., Traoré B., Coulibaly S.O., and Guiguemdé T.R. In vitro susceptibility of Burkina Faso (West Africa) 232 isolates of Plasmodium falciparum to antimalarials. Bull. Soc. Pathol. Exot. 94 (2001) 188-191
32. Trape J.F. The public health impact of chloroquine resistance in Africa. Am. J. Trop. Med. Hyg. 64S (2001) 12-17
33. Van Dillen J., Custers M., Wensink A., Wouters B., Van Voorthuizen T., Voorn W., Khan B., Muller L., and Nevill C. A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 185-188
34. White N.J. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans. R. Soc. Trop. Med. Hyg. 88 Suppl. 1 (1994) S41-S43
35. White N.J. Why is it that antimalarial drug treatments do not always work?. Ann. Trop. Med. Parasitol. 92 (1998) 449-458